Abstract: A topical gel formulation of oxybutynin is provided that exhibits enhanced bioavailability, minimized adverse side effects and skin irritations, and improved patient compliance compared to the existing oral and transdermal formulations of oxybutynin.

Abstract: Provided are enhancing transdermal absorption compositions useful in transdermal absorption of progestins including progesterone and optionally an estrogen for contraceptive or hormone replacement and dosage forms using the novel enhancing compositions. The enhancing compositions comprise a combination of a lower alkyl ester of a polycarboxylic acid, an aliphatic monohydroxy alcohol and an aliphatic diol. Also provided are processes of administration of progestins and optionally estrogens using the novel dosage forms.

Abstract: Transdermal absorption morphinan narcotic analgesic or antagonist pharmaceutical polymer matrix dosage units have been developed which comprise a backing layer and an adjoining layer of a solid polymer matrix in which minimum effective doses of morphinan narcotic analgesic or antagonist pharmaceuticals are microdispersed and transdermally supplied. A presently preferred analgesic is hydromoprhone. The dosage units use a biologically acceptable adhesive polymer means to adhere the dosage units to the subject to be treated. The polymer matrix has dispersed one or more skin permeation enhancers. The invention also provides a process for transdermal absorption of said pharmaceuticals in at least minimum dosage amounts.

Abstract: Substantially pure compounds having the general formula ##STR1## wherein (1) ##STR2## R.sup.2 is .beta.-hydroxy and R.sup.3 and R.sup.4 together form an oxygen bridge, or (2) ##STR3## R.sup.2 and R.sup.3 together form an additional carbon-carbon bond, and R.sup.4 is hydroxy, are disclosed. These compounds exhibit antileukemic activity against P388 lymphocytic leukemia in CDF.sub.1 mice and inhibitory activity in vitro against cells derived from human epidermoid carcinoma of the nasopharynx(KB) cells.